1. Home
  2. HURA vs OPTT Comparison

HURA vs OPTT Comparison

Compare HURA & OPTT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HURA
  • OPTT
  • Stock Information
  • Founded
  • HURA 2009
  • OPTT 1984
  • Country
  • HURA United States
  • OPTT United States
  • Employees
  • HURA N/A
  • OPTT N/A
  • Industry
  • HURA
  • OPTT Electric Utilities: Central
  • Sector
  • HURA
  • OPTT Utilities
  • Exchange
  • HURA Nasdaq
  • OPTT Nasdaq
  • Market Cap
  • HURA 103.3M
  • OPTT 89.7M
  • IPO Year
  • HURA N/A
  • OPTT 2007
  • Fundamental
  • Price
  • HURA $2.33
  • OPTT $0.54
  • Analyst Decision
  • HURA Strong Buy
  • OPTT
  • Analyst Count
  • HURA 2
  • OPTT 0
  • Target Price
  • HURA $11.50
  • OPTT N/A
  • AVG Volume (30 Days)
  • HURA 475.4K
  • OPTT 4.3M
  • Earning Date
  • HURA 08-15-2025
  • OPTT 07-24-2025
  • Dividend Yield
  • HURA N/A
  • OPTT N/A
  • EPS Growth
  • HURA N/A
  • OPTT N/A
  • EPS
  • HURA N/A
  • OPTT N/A
  • Revenue
  • HURA N/A
  • OPTT $6,117,000.00
  • Revenue This Year
  • HURA N/A
  • OPTT N/A
  • Revenue Next Year
  • HURA $69.15
  • OPTT N/A
  • P/E Ratio
  • HURA N/A
  • OPTT N/A
  • Revenue Growth
  • HURA N/A
  • OPTT 24.00
  • 52 Week Low
  • HURA $1.80
  • OPTT $0.14
  • 52 Week High
  • HURA $10.49
  • OPTT $1.75
  • Technical
  • Relative Strength Index (RSI)
  • HURA N/A
  • OPTT 54.18
  • Support Level
  • HURA N/A
  • OPTT $0.45
  • Resistance Level
  • HURA N/A
  • OPTT $0.65
  • Average True Range (ATR)
  • HURA 0.00
  • OPTT 0.04
  • MACD
  • HURA 0.00
  • OPTT 0.01
  • Stochastic Oscillator
  • HURA 0.00
  • OPTT 45.55

About HURA TuHURA Biosciences Inc. Common Stock

TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

About OPTT Ocean Power Technologies Inc.

Ocean Power Technologies Inc provides intelligent maritime solutions and services that enable safer, cleaner, and more productive ocean operations for the defense and security, oil and gas, science and research, and offshore wind markets. It provides ocean data collection and reporting, marine power, offshore communications, and Maritime Domain Awareness System (MDAS) products, integrated solutions, and consulting services. The company offers its products and services to a wide range of customers, including those in government and offshore energy, oil and gas, construction, wind power, and other industries. The company has operations in North and South America, Europe, Asia and Australia.

Share on Social Networks: